Showing results (1791-1800 of 2,220) with videos related to
Sort By:
Pageof 222
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 24, 2012
Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trialsMark D Okusa, Bruce A Molitoris, Paul M Palevsky, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 24, 2012
Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settingsBruce A Molitoris, Mark D Okusa, Paul M Palevsky, et al.The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 24, 2012
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodologyPaul M Palevsky, Bruce A Molitoris, Mark D Okusa, et al.Nature Chemical Biology|June 2, 2015
SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA miceJames Palacino, Susanne E Swalley, Cheng Song, et al.Journal of Medicinal Chemistry|May 18, 2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft ModelsSummer A Baker Dockrey, Pravin Chandra, Huifen Chen, et al.Journal of Medicinal Chemistry|May 24, 2021
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary DiseaseDarren Le Grand, Martin Gosling, Urs Baettig, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 1, 2024
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonismStephen P Schauer, Chang Hoon Cho, Gloriia Novikova, et al.Pageof 222